Ovid Therapeutics Inc. (OVID)

Market Cap	84.46M
Revenue (ttm)	567,695
Net Income (ttm)	-29.75M
Shares Out	70.97M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	128,443
Open	1.200
Previous Close	1.220
Day's Range	1.170 - 1.220
52-Week Range	0.680 - 4.100
Beta	0.39
Analysts	Strong Buy
Price Target	4.04 (+239.5%)
Earnings Date	Nov 1, 2024

About OVID

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 5, 2017
• Employees: 40
• Stock Exchange: NASDAQ
• Ticker Symbol: OVID
• Website: https://www.ovidrx.com

Financial Performance

In 2023, Ovid Therapeutics's revenue was $391,695, a decrease of -73.93% compared to the previous year's $1.50 million. Losses were -$52.34 million, -3.38% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for OVID stock is "Strong Buy." The 12-month stock price forecast is $4.04, which is an increase of 239.50% from the latest price.

Price Target

$4.04

(239.50% upside)

Analyst Consensus: Strong Buy